The lancet oncology
-
The lancet oncology · Jul 2015
Randomized Controlled Trial Comparative StudyPatient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
The combined efficacy analysis of the TEXT and SOFT trials showed a significant disease-free survival benefit with exemestane plus ovarian function suppression (OFS) compared with tamoxifen plus OFS. We present patient-reported outcomes from these trials. ⋯ Pfizer, International Breast Cancer Study Group, and US National Cancer Institute.
-
The lancet oncology · Jul 2015
ReviewDiagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.
The management of primary CNS lymphoma is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the very few controlled studies available. In 2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. ⋯ Specifically, we address aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients. The guidelines should aid clinicians in their daily practice and decision making, and serve as a basis for future investigations in neuro-oncology.
-
The lancet oncology · Jul 2015
Randomized Controlled Trial Comparative StudyNivolumab for squamous-cell non-small-cell lung cancer.
-
The lancet oncology · Jul 2015
Randomized Controlled Trial Comparative StudyPalbociclib for hormone receptor-positive breast cancer.